Dr. Reddy's, Sygnis Sign AX200 Agreement

Indian drugmaker Dr. Reddy’s Laboratories and Germany’s Sygnis Pharma have signed a 10-year agreement for the supply of the active ingredient AX200, a biological molecule Sygnis is developing for stroke and other neurodegenerative disorders.

The agreement secures the supply of the molecule through clinical development and provides a basis for marketing.

Sygnis completed a Phase IIa trial with AX200 in September in patients and plans to start a Phase IIb trial in the second half of 2008, Dr. Reddy’s said.